Uciane Scarlett, PhD (Guarini ‘11), is a Principal at MPM BioImpact, a leading life sciences venture firm with over $1.5B in active funds, a track record of over 50 FDA-approved drugs, and a long history of starting new therapeutics companies. At MPM BioImpact, Uciane focuses on venture investing, company creation, and operations within several of MPM’s portfolio companies. Uciane also manages MPM’s novel venture philantrophy collaboration with Dana-Farber Cancer Institute as well as several LP relationships for MPM BIoImpact’s various funds. Uciane sits on the board of several stealth-stage companies within MPM BioImpact’s portfolio.
Prior to joining MPM BioImpact, Uciane held investment roles at global-leading firms. Uciane was a Principal at Oxford Sciences Enterprise (OSE, UK), an Oxford-affiliated firm, that raised ~$1B in 2015/6, where she initially co-led the life science sector. While at OSE, Uciane led financings and drove company creation efforts for several companies including T-Cypher Bio, where she served as interim Executive Chair, PepGen (NASDAQ:PEPG) and Endlyz. She represented OSE on the boards of T-Cypher Bio, PepGen (NASDAQ:PEPG), Miro Bio (acquired by Gilead), Scenic Bio, and DJS (acquired by AbbVie).
Prior to OSE, Uciane was on the investment team at Atlas Venture where she drove company creation, operations, and financings activities for Dyne Therapeutics (NASDAQ:DYN) and Quench Bio and served in operational roles for AVROBIO (NASDAQ:AVRO) and KorroBio (NASDAQ:KRRO).
Uciane was the Director of BD & Strategy at Compass Therapeutics (NASDAQ:CMPX) and started her career after graduate school as a consultant at the life sciences consultancy, Clarion (now Clarion|Lumanity).
Uciane holds several advisory board roles, including for the Prix Galien USA and affiliated Awards. The Prix Galien Awards were created in 1970 to honor biomedical research and medical technology products that improve the human condition. Uciane also sits on the board of the Massachusetts Life Science Center and is the founder and host of the annual industry fundraising summit, Emerging Frontiers in Oncology.
Uciane holds a PhD in cancer immunology from Dartmouth College. She received her BSc, first-class honors, in biotechnology (major) and zoology (minor) from the University of the West Indies.